Abstract
A pharmacokinetic study was carried out on six normal healthy adults with average creatinine clearances ranging from 94.8 to 129.3 ml/min. Cefamandole, 15 mg/kg, was administered intravenously over a period of 10 min. Frequent and prolonged samplings of blood and urine were made. Specimens were assayed by a sensitive, accurate, and reproducible HPLC assay. An excellent computer fit to a threecompartment body model was observed. T1/2 α, β, and γ were 5.1, 23.6, and 74.2 min, respectively. The relatively long terminal T1/2 and the area under the curve (AUC) contributed by the γ phase being 31% suggest that a multicompartmental kinetic nature of cefamandole cannot be ignored. Volume of distribution (VDSS)averaged 11.8 liters, and the serum clearance was 200 ml/min. Ninetysix percent was excreted in the urine, and therefore a very high urinary concentration was achieved. The concentration in the plasma exceeds the MIC of many grampositive and negative organisms for many hours.
Similar content being viewed by others
References
L. Weinstein. Chemotherapy of microbial diseases. In L. S. Goodman and A. Gilman (eds.),Pharmacological Basis of Therapeutics, 5th ed., Macmillan, New York, 1975, pp. 1158–1166.
L. Weinstein and K. Kaplan. The cephalosporins: Microbiological, chemical and pharmacological properties and use in chemotherapy of infection.Ann. Int. Med. 72:729–739 (1970).
L. Verbist. Comparison of antimicrobiol activity of nine cephalosporins against Enterobacteriaceae and nonfermentative gram-negative bacilli.Antimicrob. Agents Chemother. 10:657–663 (1976).
M. Barza, S. Melethil, S. Berger, and E. C. Ernst. Comparative pharmacokinetics of cefamandole, cephapirin, and cephalothin in healthy subjects and effect of repeated dosing.Antimicrob. Agents Chemother. 10:421–426 (1976).
I. W. Fong, E. D. Ralph, E. R. Engelking, and W. M. M. Kirby. Clinical pharmacology of cefamandole as compared with cephalothin.Antimicrob. Agents Chemother. 9:65–69 (1976).
R. S. Griffith, H. R. Black, G. L. Brier, and J. D. Wolny. Cefamandole:In vitro and clinical pharmacokinetics.Antimicrob. Agents Chemother. 10:814–823 (1976).
W. E. Grose, G. P. Bodey, and D. Steward. Observations in man on some pharmacologic features of cefamandole.Clin. Phamacol. Ther. 20:579–584 (1976).
B. R. Meyers, B. Ribner, S. Yancovitz, and S. Z. Hirschman. Pharmacological studies with cefamandole in human volunteers.Antimicrob. Agents Chemother. 9:140–144 (1976).
N. K. Shemonsky, J. Carrizosa, and M. E. Levison.In vitro activity and pharmacokinetics in patients on cefamandole, a new cephalosporin antibiotic.Antimicrob. Agents Chemo ther. 8:679–683 (1975).
G. P. Bodey and S. Weaver.In vitro studies of cefamandole.Antimicrob. Agents Chemother. 9:452–457 (1976).
S. Eykyn, C. Jenkins, A. King, and I. Phillips. Antibacterial activity of cefamandole, a new cephalosporin antibiotic, compared with that of cephaloridine, cephalothin, and cephalexin.Antimicrob. Agents Chemother. 3:657–661 (1973).
R. N. Jones and P. C. Fuchs. Comparisons ofin vitro antimicrobial activity of cefamandole and cefazolin with cephalothin against over 8000 clinical bacterial isolates.Antimi crob. Agents Chemother. 9:1066–1069 (1976).
H. C. Neu. Cefamandole, a cephalosporin antibiotic with an unusually wide spectrum of activity.Antimicrob. Agents Chemother. 6:177–182 (1974).
T. C. Eickhoff and J. M. Ehret.In vitro comparison of cefoxitin, cefamandole, cephalexin and cephalothin.Antimicrob. Agents Chemother. 9:994–999 (1976).
E. C. Ernst, S. Berger, M. Barza, N. V. Jacobus, and F. P. Tally. Activity of cefamandole and other cephalosporins against aerobic and anaerobic bacteria.Antimicrob. Agents Chemother. 9:852–855 (1976).
B. R. Meyers, B. Leng, and S. Z. Hirschman. Cefamandole: Antimicrobial activityin vitro of a new cephalosporin.Antimicrob. Agents Chemother. 8:737–741 (1975).
E. T. Lin, J. G. Gambertoglio, N. S. Aziz, and L. Z. Benet. Determination of cefamandole in human plasma and urine using high pressure liquid chromatography. InAbstracts, 21st National Meeting of the APhA Academy of Pharmaceutical Sciences, Orlando, Vol. 6, Washington, D. C., 1976, p. 146.
C. M. Metzler,NONLIN, a Computer Program for Parameter Estimation in Nonlinear Situations, Upjohn Co. Kalmazoo, Mich. 1969.
L. Z. Benet. General treatment of linear mammillary models with elimination from any compartment as used in pharmacokinetics.J. Pharm. Sci. 61:536–541 (1972).
M. Gibaldi and D. Perrier.Pharmacokinetics, Dekker, New York, 1975, pp. 45–96.
L. Z. Benet and R. L. Galeazzi. Noncompartmental determination of the volume of distribution steady-state.J. Pharm. Sci. (in press).
L. Z. Benet. Choice of appropriate predicting models in multiple dose chemotherapy. Proceedings of the Tenth International Congress of Chemotherapy, Zurich, 1977.
C. H. Nightingale, D. S. Greene, and R. Quintiliani. Pharmacokinetics and clinical use of cepholosporin antibiotics.J. Pharm. Sci. 64:1899–1927 (1975).
C. M. Findell and J. C. Sherris. Susceptibility ofEnterobacter to cefamandole: Evidence for a high mutation rate to resistance.Antimicrob. Agents Chemother. 9:970–974 (1976).
J. H. Pennington and F. O. Grady. Reversal of the action of peniciIIin.Nature 213:34–35 (1967).
N. G. Waterman, H. U. Eikenberg, and L. Scharfenberger. Concentration of cefamandole in serum, interstitial fluid, bile and urine.Antimicrob. Agents Chemother. 10:733–735 (1976).
Author information
Authors and Affiliations
Additional information
This investigation was supported in part by a grant from Lilly Research Laboratories. During the course of this work, Dr. Aziz received support as a Postdoctoral Research Fellow in Clinical Pharmacology from Universiti Kebangsaan Malaysia.
Rights and permissions
About this article
Cite this article
Aziz, N.S., Gambertoglio, J.G., Lin, E.T. et al. Pharmacokinetics of cefamandole using a HPLC assay. Journal of Pharmacokinetics and Biopharmaceutics 6, 153–164 (1978). https://doi.org/10.1007/BF01117449
Received:
Revised:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF01117449